The efficacy and toxicity of S-1 and cisplatin as first-line chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma

被引：0
|
作者：
Han Sang Kim
Hye Ryun Kim
Gun Min Kim
Hyo Song Kim
Yoon Woo Koh
Se Hun Kim
Eun Chang Choi
Yun Kyoung Hong
Ji Hee Sung
Sun Mi Kim
Joo Hang Kim
Byoung Chul Cho
机构：
[1] Yonsei University College of Medicine,Division of Medical Oncology, Yonsei Cancer Center
[2] Yonsei University College of Medicine,Department of Otorhinolaryngology
[3] JE UK Institute for Cancer Research,Brain Korea 21 Project for Medical Sciences
[4] Yonsei University College of Medicine,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2012年 / 70卷
关键词：
Head and neck cancer; S-1; Cisplatin; Recurrent; Metastatic;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：539 / 546
页数：7
相关论文
共 50 条
  • [1] The efficacy and toxicity of S-1 and cisplatin as first-line chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma
    Kim, Han Sang
    Kim, Hye Ryun
    Kim, Gun Min
    Kim, Hyo Song
    Koh, Yoon Woo
    Kim, Se Hun
    Choi, Eun Chang
    Hong, Yun Kyoung
    Sung, Ji Hee
    Kim, Sun Mi
    Kim, Joo Hang
    Cho, Byoung Chul
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 70 (04) : 539 - 546
  • [2] Paradigm Change in First-Line Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma
    Borcoman, Edith
    Marret, Gregoire
    Le Tourneau, Christophe
    CANCERS, 2021, 13 (11)
  • [3] Capecitabine and lapatinib for the first-line treatment of metastatic/recurrent head and neck squamous cell carcinoma
    Weiss, Jared M.
    Bagley, Stephen
    Hwang, Wei-Ting
    Bauml, Joshua
    Olson, Juneko Grilley
    Cohen, Roger B.
    Hayes, David Neil
    Langer, Corey
    CANCER, 2016, 122 (15) : 2350 - 2355
  • [4] Immunotherapy, Chemotherapy, or Both: Options for First-Line Therapy for Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
    Ho, Alan L.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (04) : 736 - +
  • [5] First-line versus second-line immunotherapy in recurrent/metastatic squamous cell carcinoma of the head and neck
    Even, C.
    Torossian, N.
    Ibrahim, T.
    Martin, N.
    Badis, L. Mayache
    Ferrand, F. R.
    Iacob, M.
    Guigay, J.
    Le Tourneau, C.
    Daste, A.
    Saada-Bouzid, E.
    Saleh, K.
    ANNALS OF ONCOLOGY, 2019, 30
  • [6] Cisplatin plus Capecitabine as First-Line Chemotherapy for Recurrent or Metastatic Head and Neck Squamous Cell Cancer: Experience Outside of a Trial Setting
    McPartlin, A. J.
    Mais, K.
    Barker, C.
    Swindell, R.
    Mitchell, K.
    Sykes, A.
    Lee, L.
    Yap, B.
    Slevin, N. J.
    CHEMOTHERAPY, 2013, 59 (01) : 1 - 7
  • [7] DOCETAXEL PLUS CISPLATIN AS FIRST-LINE CHEMOTHERAPY IN PATIENTS WITH RECURRENT OR METASTATIC HEAD AND NECK CANCER
    Ohhara, Y.
    Nishimura, N.
    Nara, E.
    Nakano, K.
    Ueda, K.
    Sakajiri, S.
    Mishima, Y.
    Yokoyama, M.
    Terui, Y.
    Takahashi, S.
    Hatake, K.
    ANNALS OF ONCOLOGY, 2012, 23 : 125 - 125
  • [8] Chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck
    Fanucchi, M
    Khuri, FR
    SEMINARS IN ONCOLOGY, 2004, 31 (06) : 809 - 815
  • [9] Safety and efficacy of S-1 chemotherapy in recurrent/metastatic head and neck cancer
    Suzuki, Shinsuke
    Ishikawa, Kazuo
    JOURNAL OF INFECTION AND CHEMOTHERAPY, 2009, 15 (05) : 335 - 339
  • [10] Efficacy and safety of pembrolizumab in recurrent or metastatic head and neck carcinoma as first-line therapy
    Ito, K.
    Nakanome, A.
    Morita, S.
    Imai, T.
    Asada, Y.
    ANNALS OF ONCOLOGY, 2024, 35 : S1402 - S1402
12345